TD Cowen upgraded shares of Standard BioTools (NASDAQ:LAB - Free Report) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.
Standard BioTools Stock Down 1.6%
LAB traded down $0.02 during trading on Thursday, reaching $1.23. The company's stock had a trading volume of 1,489,651 shares, compared to its average volume of 1,915,480. The firm has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $1.26. Standard BioTools has a 1 year low of $0.92 and a 1 year high of $2.41. The company has a market cap of $467.18 million, a price-to-earnings ratio of -3.51 and a beta of 1.54.
Institutional Trading of Standard BioTools
Several institutional investors have recently made changes to their positions in LAB. Jump Financial LLC purchased a new stake in Standard BioTools in the first quarter valued at approximately $26,000. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Standard BioTools in the fourth quarter valued at approximately $29,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock valued at $29,000 after purchasing an additional 14,541 shares during the period. Two Sigma Securities LLC purchased a new stake in Standard BioTools in the fourth quarter valued at approximately $30,000. Finally, CWM LLC raised its position in Standard BioTools by 101.8% in the first quarter. CWM LLC now owns 29,705 shares of the company's stock valued at $32,000 after purchasing an additional 14,984 shares during the period. Hedge funds and other institutional investors own 53.74% of the company's stock.
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
See Also
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
